Haemonetics Statistics
Want to see HAE full AI Analyst Report?
Haemonetics (HAE) Stock Statistics & Valuation Metrics
Total Valuation
Haemonetics has a market cap or net worth of $5.57B. The enterprise value is $5.76B.
- Market Cap
- $5.57B
- Enterprise Value
- $5.76B
Share Statistics
Haemonetics has 45,537,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 45,537,510
- Owned by Insiders
- 1.82%
- Owned by Institutions
- 76.05%
Financial Efficiency
Haemonetics’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.66%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 8.66%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 443.35K
- Profits Per Employee
- 32.34K
- Employee Count
- 3,009
- Asset Turnover
- 0.56
- Inventory Turnover
- 1.93
Valuation Ratios
The current PE Ratio of Haemonetics is 53.10. Haemonetics’s PEG ratio is -1.56.
- PE Ratio
- 53.10
- PS Ratio
- 3.97
- PB Ratio
- 6.10
- Price to FCF
- 18.07
- Price to Operating Cash Flow
- 15.90
- PEG Ratio
- -1.56
Income Statement
In the last 12 months, Haemonetics had revenue of 1.33B and earned 97.31M in profits. Earnings per share was 2.05.
- Revenue
- 1.33B
- Gross Profit
- 743.59M
- Operating Income
- 241.40M
- Pretax Income
- 128.03M
- Net Income
- 97.31M
- EBITDA
- 268.45M
- Earnings Per Share (EPS)
- 2.05
Cash Flow
In the last 12 months, operating cash flow was 344.93M and capital expenditures -41.12M, giving a free cash flow of 303.81M billion.
- Operating Cash Flow
- 344.93M
- Free Cash Flow
- 303.81M
- Free Cash Flow per Share
- 6.68
Dividends & Yields
Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.53%
- Earnings Yield
- 1.89%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- 68.05%
- 50-Day Moving Average
- 111.45
- 200-Day Moving Average
- 80.02
- Relative Strength Index (RSI)
- 55.08
- Average Volume (3m)
- 714.35K
Important Dates
Haemonetics upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Haemonetics as a current ratio of 2.95, with Debt / Equity ratio of 153.78%
- Current Ratio
- 2.95
- Quick Ratio
- 1.87
- Debt to Market Cap
- 0.48
- Net Debt to EBITDA
- 3.65
- Interest Coverage Ratio
- 8.41
Taxes
In the past 12 months, Haemonetics has paid 30.72M in taxes.
- Income Tax
- 30.72M
- Effective Tax Rate
- 0.24
Enterprise Valuation
Haemonetics EV to EBITDA ratio is 22.93, with an EV/FCF ratio of 20.93.
- EV to Sales
- 4.60
- EV to EBITDA
- 22.93
- EV to Free Cash Flow
- 20.93
- EV to Operating Cash Flow
- 18.44
Balance Sheet
Haemonetics has $260.71M in cash and marketable securities with $1.12B in debt, giving a net cash position of -$863.05M billion.
- Cash & Marketable Securities
- $260.71M
- Total Debt
- $1.12B
- Net Cash
- -$863.05M
- Net Cash Per Share
- -$18.95
- Tangible Book Value Per Share
- -$4.07
Margins
Gross margin is 58.83%, with operating margin of 18.34%, and net profit margin of 7.52%.
- Gross Margin
- 58.83%
- Operating Margin
- 18.34%
- Pretax Margin
- 10.27%
- Net Profit Margin
- 7.52%
- EBITDA Margin
- 20.06%
- EBIT Margin
- 12.14%
Analyst Forecast
The average price target for Haemonetics is $145.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $145.14
- Price Target Upside
- 20.41% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- 4.11%
- EPS Growth Forecast
- -34.22%
Scores
- Smart Score
- 10
- AI Score
- 72.4
